Keyphrases
Inflammatory Bowel Disease
100%
Fecal Microbiota Transplantation
33%
Clostridioides Difficile
30%
Clostridium Difficile Infection
21%
Ulcerative Colitis
19%
Colonoscopy
19%
Crohn's Disease
15%
Primary Sclerosing Cholangitis
14%
Biological Therapy
14%
Therapeutic Potential
13%
University Centers
12%
Eosinophilic Esophagitis
12%
Recurrent Infection
12%
Endoscopic Findings
11%
Small Molecules
10%
Inflammatory Activity
10%
Gastrointestinal Diseases
10%
Chile
9%
Chilean
9%
Pathological Findings
9%
Remission
9%
Liver
8%
Corticosteroids
8%
Eosinophil Count
8%
Colorectal Cancer
8%
Endoscopic Score
7%
Proton Pump Inhibitors
7%
Active Disease
7%
Janus Kinase Inhibitors
7%
Cardiovascular Risk
7%
Pregnant Women
6%
Adverse Events
6%
Herpes Esophagitis
6%
Chilean Universities
6%
Overlap Syndrome
6%
Pouchitis
6%
Autoimmune Hepatitis
6%
University Hospital
6%
Herpes Simplex Virus
6%
Drug-induced Liver Injury
6%
Immunization
6%
Intestine
6%
Collagenous Colitis
6%
Psoriatic Arthritis
6%
Leflunomide
6%
Anemia
6%
Intestinal Inflammation
6%
Sigmoidoscopy
6%
Older Patients
6%
Treat-to-target
6%
Medicine and Dentistry
Inflammatory Bowel Disease
84%
Infection
24%
Fecal Microbiota Transplantation
24%
Colonoscopy
19%
Disease
17%
Ulcerative Colitis
15%
Primary Sclerosing Cholangitis
13%
Patient with Inflammatory Bowel Disease
12%
Eosinophilic Esophagitis
12%
Transplantation
12%
Recurrent Infection
12%
Neoplasm
12%
Colorectal Carcinoma
10%
Crohn's Disease
10%
Biological Product
9%
Biological Therapy
8%
Gastrointestinal Disease
8%
Pouchitis
8%
Quality of Life
7%
Eosinophil
7%
Patient with Ulcerative Colitis
7%
Colon
6%
Esophagitis
6%
Diagnosis
6%
Sensitivity and Specificity
6%
Infliximab
6%
Pediatrics
6%
Sigmoidoscopy
6%
Cardiovascular Disease
6%
Personalized Medicine
6%
Intestine
6%
Squamous Cell Carcinoma
6%
Transitional Care
6%
Premedication
6%
Toxic Hepatitis
6%
Microbiome
6%
Infusion
6%
Autoimmune Hepatitis
6%
Overlap Syndrome
6%
Anemia
6%
Polyethylene Terephthalate
6%
Positron Emission Tomography-Computed Tomography
6%
Fluorine-18
6%
Health Care Cost
5%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Bowel Disease
60%
Feces microflora
24%
Infection
15%
Primary Sclerosing Cholangitis
12%
Biological Product
10%
Ulcerative Colitis
9%
Disease
9%
Adverse Event
9%
Crohn's Disease
8%
Gastrointestinal Disease
8%
Remission
7%
Janus Kinase Inhibitor
7%
Cardiovascular Disease
7%
Autoimmune Hepatitis
6%
Psoriatic Arthritis
6%
Leflunomide
6%
Collagenous Colitis
6%
Anemia
6%
Helicobacter Infection
6%
Proton Pump Inhibitor
6%
Syndrome
6%
Recurrent Infection
6%
Toxic Hepatitis
6%
Amoxicillin
6%
Intestine Flora
6%
Upadacitinib
6%
